Patients with gastric cancer or gastroesophageal junction cancer (GEJ) could experience significantly improved progression-free survival, and maybe also overall survival, with nivolumab (Opdivo) in the first-line and neoadjuvant settings, suggest data from three phase 3 trials.
However, contrasting results between the trials and question marks over the effect of the drug in all-comers leaves some questions yet to be answered, despite the “practice-changing” findings, said experts discussing the new data.
The research was presented September 21 at the ESMO Virtual Congress 2020, held online due to the COVID-19 pandemic.
Gastric cancer and GEJ have been an area of interest for immunotherapy in recent years, as standard first-line chemotherapy is associated with poor overall survival at a median of less than 1 year.
Previous smaller studies have suggested that nivolumab has promising activity in the first-line setting, improving survival particularly in individuals with a combined positive score (CPS) for programmed death